Mercury Ev-Tech Regulatory Approval

Mercury Ev-Tech Board Meeting Date

Mercury Ev-Tech Ltd scheduled a board meeting for October 31, 2026, to consider and approve financial results for the quarter ended September 30, 2026.

Mercury Ev-Tech Other Announcement

The company submitted its quarterly shareholding pattern for the period ended December 31, 2025, pursuant to Regulation 31(1)(b) of the SEBI LODR Regulations. This is a routine compliance filing.

Mercury Ev-Tech Management Change

Mercury EV-Tech Ltd appointed Mr. Shreyan Jigneshkumar Patel as an Additional Director and accepted the resignation of Mr. Lalit Vitthal Waankhede, both effective October 05, 2026.

Mercury Ev-Tech Other Announcement

Mercury Ev-Tech Ltd appointed M/s. Nisarg Sharma & Associates as its Secretarial Auditor for a five-year term, following approval at the 40th Annual General Meeting.

Execution

5 years

Mercury Ev-Tech Annual General Meeting

Mercury EV-Tech Limited held its 40th Annual General Meeting, where shareholders considered financial statements, auditor appointments, and various material related party transactions.

Mercury Ev-Tech Capacity Expansion

Mercury Ev-Tech appointed 100 new dealers nationwide and gained GEDA subsidy eligibility for Gujarat. The company targets 200 more dealers by March 2027.

dealer network expansion

100 dealers

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.